BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22512897)

  • 1. Evaluation of recurrent venous thromboembolism in patients with Factor V Leiden mutation in heterozygous form.
    Sveinsdottir SV; Saemundsson Y; Isma N; Gottsäter A; Svensson PJ
    Thromb Res; 2012 Sep; 130(3):467-71. PubMed ID: 22512897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation.
    Saemundsson Y; Sveinsdottir SV; Svantesson H; Svensson PJ
    J Thromb Thrombolysis; 2013 Oct; 36(3):324-31. PubMed ID: 23054468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender-related differences in the outcome of patients with venous thromboembolism and thrombophilia.
    Tzoran I; Papadakis E; Brenner B; Valle R; López-Jiménez L; García-Bragado F; Riera-Mestre A; Villalobos A; Quintavalla R; Monreal M;
    Thromb Res; 2017 Mar; 151 Suppl 1():S11-S15. PubMed ID: 28262227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High risk of thrombosis recurrence in patients with homozygous and compound heterozygous factor V R506Q (Factor V Leiden) and prothrombin G20210A.
    Federici EH; Al-Mondhiry H
    Thromb Res; 2019 Oct; 182():75-78. PubMed ID: 31472339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden.
    Couturaud F; Kearon C; Leroyer C; Mercier B; Abgrall JF; Le Gal G; Lacut K; Oger E; Bressollette L; Ferec C; Lamure M; Mottier D;
    Thromb Haemost; 2006 Dec; 96(6):744-9. PubMed ID: 17139368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upper extremity deep venous thrombosis in the population-based Malmö thrombophilia study (MATS). Epidemiology, risk factors, recurrence risk, and mortality.
    Isma N; Svensson PJ; Gottsäter A; Lindblad B
    Thromb Res; 2010 Jun; 125(6):e335-8. PubMed ID: 20406709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.
    Marchiori A; Mosena L; Prins MH; Prandoni P
    Haematologica; 2007 Aug; 92(8):1107-14. PubMed ID: 17650440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence.
    Sundquist K; Wang X; Svensson PJ; Sundquist J; Hedelius A; Larsson Lönn S; Zöller B; Memon AA
    Thromb Haemost; 2015 Nov; 114(6):1156-64. PubMed ID: 26245493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-specific risk factors for recurrent venous thromboembolism.
    Olié V; Zhu T; Martinez I; Scarabin PY; Emmerich J
    Thromb Res; 2012 Jul; 130(1):16-20. PubMed ID: 22100316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of inherited thrombophilia on the risk of recurrent venous thromboembolism onset in Georgian population.
    Pirtskhelani N; Kochiashvili N; Makhaldiani L; Pargalava N; Gaprindashvili E; Kartvelishvili K
    Georgian Med News; 2014 Feb; (227):93-7. PubMed ID: 24632656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor V 1691 G-A (Leiden) polymorphism and cancer-related venous thromboembolism: a meta-analysis of published studies.
    Eroglu A; Sertkaya Karasoy D; Eroglu N; Akar N
    J BUON; 2008; 13(1):61-4. PubMed ID: 18404788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obstetric complications and pregnancy-related venous thromboembolism: the effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation.
    Tormene D; Grandone E; De Stefano V; Tosetto A; Palareti G; Margaglione M; Castaman G; Rossi E; Ciminello A; Valdrè L; Legnani C; Tiscia GL; Bafunno V; Carraro S; Rodeghiero F; Simioni P
    Thromb Haemost; 2012 Mar; 107(3):477-84. PubMed ID: 22273731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members.
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2011 Jan; 13(1):67-76. PubMed ID: 21150787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type and location of venous thromboembolism in carriers of Factor V Leiden or prothrombin G20210A mutation versus patients with no mutation.
    Kovac M; Mitic G; Mikovic Z; Antonijevic N; Djordjevic V; Mikovic D; Mandic V; Rakicevic L; Radojkovic D
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):66-70. PubMed ID: 18796457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of factor V G1691A (Leiden) and prothrombin G20210A polymorphisms among apparently healthy Jordanians.
    Nusier MK; Radaideh AM; Ababneh NA; Qaqish BM; Alzoubi R; Khader Y; Mersa JY; Irshaid NM; El-Khateeb M
    Neuro Endocrinol Lett; 2007 Oct; 28(5):699-703. PubMed ID: 17984931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
    Sonnevi K; Tchaikovski SN; Holmström M; Rosing J; Bremme K; Lärfars G
    Thromb Haemost; 2011 Nov; 106(5):901-7. PubMed ID: 21947267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review.
    Segal JB; Brotman DJ; Necochea AJ; Emadi A; Samal L; Wilson LM; Crim MT; Bass EB
    JAMA; 2009 Jun; 301(23):2472-85. PubMed ID: 19531787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombophilia and venous thromboembolism in pregnancy: a meta-analysis of genetic risk.
    Ziakas PD; Poulou LS; Pavlou M; Zintzaras E
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():106-11. PubMed ID: 26115054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do incident and recurrent venous thromboembolism risks truly differ between heterozygous and homozygous Factor V Leiden carriers? A retrospective cohort study.
    Perez Botero J; Ormsby WD; Ashrani AA; McBane RD; Wysokinski WE; Patnaik MM; Lewis BR; Grill DE; Pruthi RK; Heit JA
    Eur J Intern Med; 2016 May; 30():77-81. PubMed ID: 26970916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
    Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Minar E; Lechner K; Kyrle PA
    Thromb Haemost; 1997 Apr; 77(4):624-8. PubMed ID: 9134632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.